Tred’s post wording in regards to biomarkers seems ok to me.
The biomarkers are as you say specific to how efficacious A2-73 is, although it seems only by a small margin, depending on the wild type vs. specific variants of the COMT and SIGMAR1 genes regardless of indication.
I think the genetic biomarkers will help in validating A2-73 as having predictable features and possibly provide further insight to neurological disease pathways, which can’t be bad for regulatory approval. How clinical meaningful those biomarkers are remains to be seen.
Market Data 
Markets 
AI
